Sir,
Adalimumab is a human monoclonal antibody to tumor necrosis factor (TNF)-a approved for treatment of many chronic inflammatory diseases. Although generally a well-tolerated biologic agent, there are reports of local side effects, lupus-like rash, 1 or systemic lupus erythematosus (SLE) 2 associated with TNF-a inhibitors.
Lupus erythematous panniculitis (LEP) is a rare variant of cutaneous lupus erythematous (CLE) that can occur alone or in combination with SLE. Its incidence is about 1-3% of CLE. Here, we report a first case of LEP induced by TNF-a inhibitor in a patient who received adalimumab for rheumatoid arthritis.
A 49-year-old female in a remission status of SLE diagnosed 22 years ago and active rheumatoid arthritis diagnosed 18 years ago had poor compliance to cyclosporine and methotrexate in controlling arthritis. With adequate C-reactive protein response and anti-CCP antibodies, she was considered as a 'Rhupus' patient with possibility of lupus flare. Nevertheless, she underwent an adalimumab trial due to uncontrolled arthritis. Manifestations of SLE were not present at the time of injection, and it significantly improved her arthritis. But after the fourth injection, erythematous, indurated subcutaneous plaques developed along the injection site of the patient's arm (Figure 1(a) ). The patient's concern about the skin rash grew, and treatment was discontinued.
Although the lesions stopped progressing after cessation of adalimumab, they remained unchanged for two more years. A skin biopsy performed at this period showed atrophic epidermis with mild vacuolar degeneration and mucin throughout the dermis. Substantial lymphocytic inflammation in subcutaneous fat was distributed in lobular panniculitis pattern, and conclusive pathological diagnosis was LEP (Figure 1(b) and (c)). Pericardial effusion, nephritis, lymphocytopenia, hemolytic anemia, polyarthritis, symptoms that were present during the patient's initial diagnosis of SLE, were not present. ANA was still positive but decreased in titration during two decades (from 1:640 to 1:160). With treatment of hydroxychloroquine, the lesions disappeared gradually over eight months. There has been no sign of recurrence in three years of follow up.
The mechanism for adalimumab-induced CLE is uncertain. Several proposed mechanisms are neutralization of TNF-a promoting humoral autoimmunity through cytotoxic T lymphocyte, 3 suppression of Th1 mediated immune response and shift towards lupus-favorable Th2, 4 and decreased cellular expression of adhesion molecule CD44 resulting in impaired clearance of apoptotic cells. 2 Also, neutralization of TNF-a increases production of IFN-a by plasmacytoid dendritic cells, and many IFN-a up-regulated genes are associated with cutaneous lupus. 5 There have been previous reports of subacute LE, 6,7 discoid LE (DLE) 8, 9 and LE tumidus, 10 but none of LEP associated with TNF-a inhibitors. But as roughly 50% of patients with LEP are reported to have evidence of SLE, underlying 'Rhupus' in our patient does raise a suspicion of lupus reactivation rather than a drug-induced etiology. Yet the temporal relationship between cutaneous lesion and initiation of adalimumab and no further progression upon discontinuation of the drug more strongly supports drug-induced LEP. In conclusion, we introduce a case of LEP after adalimumab injection deserving attention as being the first case to be reported. 
